DGAP-News: Epigenomics: US study suggests blood-based Septin9 CRC screening could save lives and be health-economically beneficial
(firmenpresse) - DGAP-News: Epigenomics AG / Key word(s): Study
Epigenomics: US study suggests blood-based Septin9 CRC screening could
save lives and be health-economically beneficial
22.07.2013 / 10:30
---------------------------------------------------------------------
Press release
Epigenomics: US study suggests blood-based Septin9 CRC screening could save
lives and be health-economically beneficial
- CRC screening with blood-based Septin9 tests has potential to improve
screening uptake and adherence rates
- Septin9 testing could decrease colorectal cancer (CRC) incidence by 41%
and CRC mortality by 61% at optimal screening uptake rates
- Septin9 based screening shown to be cost-effective over no screening
Berlin, Germany, and U.S.A., July 22, 2013 - Epigenomics AG (Frankfurt
Prime Standard: ECX), the German-American cancer molecular diagnostics
company, today announced findings from a health economic study by Prof. Uri
Ladabaum, M.D., M.S., et al. from the Division of Gastroenterology and
Hepatology, Stanford University School of Medicine, USA.
According to the study, Septin9 testing provides potential for saving lives
while being health economically beneficial as an attractive screening
alternative to established methods for a population that would otherwise be
non-compliant to colorectal cancer screening.
The study, which was published in 'Cancer Epidemiology, Biomarkers&Prevention', concluded that Septin9 tests would decrease CRC incidence by
41% and CRC mortality by 61% assuming optimal uptake. In addition, Septin9
tests have the potential to demonstrate significant economic benefits at
acceptable costs by increasing screening rates and improving adherence over
time compared to other strategies. At 75% adherence with the blood-based
Septin9 test, compared to under 20% with stool-based tests (FIT) per
screening cycle, Septin9 based CRC screening would be cost-effective. In
the comparison, current FIT tests would be more effective and less costly
than all other alternatives, assuming optimal uptake, adherence and
follow-up, but this has not yet been achieved in practice.
'Colorectal cancer is the third most common cancer globally and the second
most common cancer in industrialized countries. As observed in other cancer
indications, screening and early detection of cancers could decrease
mortality significantly. Although established screening strategies are very
effective and cost efficient, compliance rates are devastatingly low due to
the partly invasive and/or uncomfortable nature of the established
screening methods. At least one of three eligible US citizens does not
undergo CRC screening, resulting in more than 60% of CRC cases being
detected in late, symptomatic stages,' explained Dr. Thomas Taapken,
CEO/CFO of Epigenomics AG. 'CRC screening with a convenient blood test has
the potential to significantly improve screening uptake and adherence and
ultimately reduce CRC incidence and mortality, as well as resulting
healthcare cost.'
The basis for comparison between different screening methods in the
Ladabaum study were the published results of the PRESEPT study, run with a
prototype version of the Septin9 assay, and historical FIT data. There were
no direct comparison data between the two methods at the time. Epigenomics
recently conducted a head-to-head comparison study between its Epi
proColon(R) test, currently under PMA review by the FDA, and FIT
demonstrating non-inferiority of Epi proColon(R) to FIT with respect to
sensitivity. The achieved sensitivity for Epi proColon was 73%, compared to
68% for FIT.
- Ends -
Contact Epigenomics AG
Antje Zeise, Manager IR | PR
Epigenomics AG
Kleine Praesidentenstrasse 1
10178 Berlin
Tel. +49 (0) 30 24345 386
ir(at)epigenomics.com
www.epigenomics.com
For US press inquiries:
Epigenomics, Inc.
9700 Great Seneca Highway Rockville
Maryland 20850
pr(at)epigenomics.com
About Epigenomics
Epigenomics (www.epigenomics.com) is a molecular diagnostics company
developing and commercializing a pipeline of proprietary products for
cancer. The Company's products enable doctors to diagnose cancer earlier
and more accurately, leading to improved outcomes for patients.
Epigenomics' lead product, Epi proColon(R), is a blood-based test for the
early detection of colorectal cancer, which is currently marketed in Europe
and is in development for the U.S.A. The Company's technology and products
have been validated through multiple partnerships with leading global
diagnostic companies and testing laboratories. Epigenomics is an
international company with operations in Europe and the U.S.A.
Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements
involve certain known and unknown risks, uncertainties and other factors
which could cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Epigenomics AG is providing this communication
as of this date and does not undertake to update any forward-looking
statements contained herein as a result of new information, future events
or otherwise.
The information contained in this communication does not constitute nor
imply an offer to sell or transfer any product, and no product based on
this technology is currently available for sale by Epigenomics in the
United States or Canada. The analytical and clinical performance
characteristics of any Epigenomics product based on this technology which
may be sold at some future time in the U.S. have not been established.
End of Corporate News
---------------------------------------------------------------------
22.07.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Epigenomics AG
Kleine Präsidentenstraße 1
10178 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir(at)epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A1K0516
WKN: A1K051
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
222217 22.07.2013
Themen in dieser Pressemitteilung:
epigenomics-us-study-suggests-blood
based-septin9-crc-screening-could-save-lives-and-be-health
economically-beneficial
Unternehmensinformation / Kurzprofil:
Datum: 22.07.2013 - 10:30 Uhr
Sprache: Deutsch
News-ID 280282
Anzahl Zeichen: 8973
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 296 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Epigenomics: US study suggests blood-based Septin9 CRC screening could save lives and be health-economically beneficial"
steht unter der journalistisch-redaktionellen Verantwortung von
Epigenomics AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
